Why You Can't Sleep on Peptides

Your body runs on glucose the way a car runs on fuel, and when the tank runs low in the middle of the night, your brain does not quietly wait for morning.

It hits the alarm.

That alarm comes in the form of cortisol and adrenaline, two hormones that your body releases specifically to pull blood glucose back up when it drops too low during sleep. The cortisol spike does its job, glucose rises, and you wake up at two or three in the morning feeling alert and wired for no reason you can identify. It does not feel like a blood sugar problem. It feels like insomnia. But the sleep is not the problem. The blood sugar is.

Now layer peptides on top of that system and you have two very different mechanisms that can both trigger the same outcome, depending on what you are taking.

The first mechanism involves something called incretin mimetics, which are compounds like semaglutide, tirzepatide, and retatrutide that work by mimicking gut hormones to suppress appetite and slow gastric emptying. They do this extremely well. In the phase 2 trial for retatrutide, participants lost an average of 24.2 percent of their body weight at the 12mg dose, and that kind of result does not happen without a dramatic reduction in how much food people are actually eating day to day. The problem is that appetite suppression does not come with a warning label that says "you are now underfueling." People on these compounds often eat far less than they realize, which means they go into the night with less stored fuel, which means blood glucose runs out of runway faster while they sleep.

The fix for this one is straightforward. You need to eat enough during the day, even if you do not feel hungry, because the hunger signal that would normally remind you is being pharmacologically suppressed.

If you are low carb or ketogenic, this may be less of an issue because your body has adapted to run on fat and ketones and uses something called gluconeogenesis, which is the process by which your liver manufactures glucose from non-carbohydrate sources like protein and glycerol, to keep blood sugar stable. The adaptation is real and it works, but it works because your cells have become efficient at the process, not because you can eat almost nothing and expect it to function. When a drug suppresses appetite to the point where total caloric intake collapses, gluconeogenesis does not have enough raw material to compensate. The issue is not the diet. The issue is the deficit.

The second mechanism is entirely different and it involves something called GH secretagogues, which are compounds like CJC-1295, ipamorelin, and tesamorelin that work by stimulating your pituitary gland to release pulses of growth hormone. People typically inject these before bed to align with the body's natural overnight GH pulse, which is the largest of the day. This is a reasonable strategy for maximizing the GH signal. The problem is what growth hormone does to blood sugar.

Growth hormone is anti-insulin. That is not a side effect, it is a core part of how the molecule functions. It shifts the body toward fat oxidation and away from glucose oxidation, which means it actively reduces how sensitive your tissues are to insulin and how efficiently they take up glucose from the blood. Research on GH's metabolic effects shows it antagonizes insulin through at least two pathways: it increases circulating free fatty acids, which compete with glucose for uptake in muscle tissue, and it directly blunts insulin signaling at the receptor level in the liver. The result is that hepatic glucose production rises while peripheral glucose clearance falls.

This is so well characterized that researchers studying something called the dawn phenomenon, which is the early morning rise in blood glucose that many people with type 1 diabetes experience, were able to reproduce it entirely by manipulating GH. When nocturnal GH spikes were suppressed with somatostatin, the dawn phenomenon disappeared. When GH was restored, hepatic glucose production increased by approximately 30 percent and the phenomenon came back. The GH spike was the driver.

So when you inject a GH secretagogue before bed and your pituitary fires a significant GH pulse at midnight or one in the morning, you are creating a blood sugar swing at the exact time your body has the least food-derived glucose coming in and the least capacity to buffer it. Blood glucose drops, cortisol and adrenaline respond, and you wake up.

The practical solution here is timing. Moving the injection a couple of hours earlier in the evening rather than immediately before sleep can shift the GH pulse slightly earlier so it does not land at peak sleep depth. A small snack of protein and fat before bed also provides a slow-releasing substrate that can buffer the glucose swing, because fat slows gastric emptying and protein gives the liver material for gluconeogenesis without spiking insulin the way carbohydrates do.

If you are running both an incretin and a GH secretagogue at the same time, both mechanisms are active simultaneously. The incretin has already suppressed your appetite so you are going to bed underfueled, and the GH secretagogue is creating a blood sugar swing on top of an already shallow tank. That combination makes the nocturnal cortisol response almost inevitable if you are not deliberately managing it.

Most people chasing better sleep while on peptides are looking at melatonin doses and sleep hygiene and room temperature, and those things matter under normal circumstances, but they are solving the wrong problem when the root cause is metabolic. No amount of magnesium glycinate corrects a 30 percent increase in hepatic glucose production at two in the morning.

The compounds are doing exactly what they are supposed to do. Your body is responding to them exactly the way it is supposed to. The gap is that nobody told you the compounds were going to change your overnight metabolic environment, and your sleep strategy was built for a different body than the one you now have.

---

References

1. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness